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Abstract
Background: Platelets contribute to vascular homeostasis and angiogenesis through the release of multiple
growth factors, cytokines and nucleotides, such as ATP and ADP. Recent reports have demonstrated a marked
growth-promoting effect of total platelet extracts and selected platelet growth factors on therapeutic angiogenesis.
However, since endogenous adenine nucleotides are rapidly degraded during the platelet isolation and storage,
we examined whether supplementing a platelet-derived extract with exogenous adenine nucleotides would
augment their pro-angiogenic effects.
Methods: Pulmonary artery vasa vasorum endothelial cells (VVEC) were used to examine the effects of dialyzed
platelet-derived soluble extracts and extracellular adenine nucleotides on proliferation, migration and tube
formation. In addition, an in vivo Matrigel plug assay was used to examine the effects of platelet extracts and
adenine nucleotides on neovascularization of plugs subcutaneously placed in 50 ICR mice. The number of vascular
structures in Matrigel plugs were evaluated by histological and statistical methods.
Results: Platelet extracts (6.4-64 μg/ml) significantly induced DNA synthesis and at a concentration of 64 μg/ml
had a biphasic effect on VVEC proliferation (an increase at 48 hrs followed by a decrease at 60 hrs). Stimulation of
VVEC with platelet extracts also significantly (up to several-fold) increased cell migration and tube formation on
Matrigel. Stimulation of VVEC with extracellular ATP (100 μM) dramatically (up to ten-fold) increased migration and
tube formation on Matrigel; however, no significant effects on cell proliferation were observed. We also found that
ATP moderately diminished platelet extract-induced VVEC proliferation (48 hrs) and migration, but potentiated tube
formation. Neither ATP, or a mixture of non-hydrolyzable nucleotides (ATPgS, ADPbS, MeSATP, MeSADP) induced
vascularization of Matrigel plugs subcutaneously injected in mice, however, the combination of these nucleotides
with platelet extracts dramatically increased the number of functional capillaries in the Matrigel plugs.
Conclusion: Data from this study suggest that platelet-derived growth factors and extracellular nucleotides
represent important regulatory signals for angiogenesis. Supplementation of platelet extracts with exogenous
adenine nucleotides may reveal new possibilities for therapeutic angiogenesis and tissue regeneration approaches.
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Angiogenesis is a fundamentally important process
occurring under both physiological and pathological
conditions, including embryonic development, tumor
progression, and tissue regeneration. Regulation of
angiogenesis requires a balance between multiple pro-
and anti-angiogenic factors and involves interaction of
the vascular wall and circulating blood cells [1-3]. Plate-
lets, in addition to their role in hemostasis, can play a
critical role in the modulation of angiogenesis with the
capacity to release both pro- and anti-angiogenic factors
[4,5]. In fact, platelet-rich plasma ("PRP”) is currently
used in a variety of settings to promote wound healing.
However, the bioactivity, and optimal application of
complex mixtures isolated from platelets, analogous to
the materials currently widely used under the term
“PRP”, are not entirely understood. A better understand-
ing will lead to enhanced efficacy in these applications.
Pro-angiogenic effects of platelet-derived soluble growth
factors or platelet-derived microparticles have been
demonstrated by several approaches including the rat aor-
tic ring assay, subcutaneous agarose implants in mice [6],
in vitro Matrigel tube formation and migration assay [7],
electron microscopy, and intravital analysis of platelet in
blood vessels [7,8]. Some studies demonstrated, that the
majority of endothelial cell chemoattractant activity
was generated during blood clotting, suggesting that
platelet-released soluble factors, including lipid media-
tors are positive regulators of angiogenesis [9,10].
Whole platelets can also induce angiogenesis in the
mouse matrigel plug assay, and this effect was shown
to be dependent on multiple growth factors secreted
by platelets [11]. It has been demonstrated that the
presence of platelets not only stimulates angiogenic
vessel growth but also plays a critical role in prevent-
ing hemorrhage from the angiogenic vessels [12]. Pla-
telets have also been observed to contribute to tumor
angiogenesis. Platelets of animals bearing malignant
tumors actively sequester angiogenic mediators
(VEGD, PDGF, bFGF) against a steep gradient from
the serum, and therefore the levels of angiogenic med-
iators in the platelets can reflect the presence of an
occult tumor while serum levels do not [5].
In addition to growth factors and metalloproteinases,
platelet pro-angiogenic products also include lysopho-
spholipids, such as sphingosine 1-phosphate (SP-1),
lysophosphatidic acid (LPA) and possibly other butanol-
soluble lipids [7,9]. Recent fascinating studies of Pula
et al, demonstrated pro-angiogenic effects of thymidine
phosphorylase [13] and platelet-derived deoxyribose-1-
phosphate [14]. On the other hand, it is known that pla-
telet activating factor-4, thrombospondin-1, plasminogen
activator inhibitor-1, a2-macroglobulin, angiostatin and
kinostatin exhibit anti-angiogenic effects [15,16].
Platelets contain three types of secretory vesicles: dense
granules, a-granules, and lysosomes [17]. Pro- and anti-
angiogenic factors are stored in separate alpha-granule
populations within platelets which can be released selec-
tively in response to stimulation of specific platelet
receptors [16]. This segregation may allow sequential
release leading to safe and effective initiation and later
suppression of regenerative (proliferative and migratory)
activity during wound healing and tissue regeneration.
Although single growth factors, such as VEGF or bFGF
have been used to stimulate clinically relevant angio-
g e n i cr e s p o n s e s ,t h e yf a i l e dt od os oi ni s o l a t i o nf r o m
other components present in natural platelet mixtures
[18]. Alone, though very effective at stimulating prolif-
eration and migration of endothelial cells in culture,
these factors in vivo produced only weak and leaky
immature blood vessels [19].
Extracellular purines and pyrimidines have long been
known as regulators of vascular tone and permeability.
Moreover, recent studies in different endothelial cell
models have implicated the extracellular nucleotides in
the regulation of angiogenesis [20-23]. Platelets are an
abundant source of endogenous ATP and ADP, which
are released from dense granules in response to platelet
activation with thrombin, collagen, thromboxane or
ADP itself. Thus, extracellular ATP and ADP may regu-
late vascular inflammation and thrombosis [24-26], as
autocrine/paracrine signaling molecules. Both platelets
and endothelial cells express P2 purinergic receptors
responsive to extracellular nucleotides [27-29]. Extracel-
lular ADP stimulates platelet aggregation via the activa-
tion of P2Y1 and P2Y12 receptors, coupled to
phospholipase C and adenylate cyclase/cAMP pathways,
respectively. In turn, extracellular ATP and adenosine
antagonize the platelet aggregation response. Impor-
tantly, a recent study demonstrated that P2Y-mediated
platelet activation resulted in release of VEGF and endo-
statin [30], indicating an involvement of platelets in pur-
inergic regulation of angiogenesis.
As platelets are important to the angiogenic process,
delivery of intact and “healthy” platelets (or their overall
constituents) to a site of neovascularization would prob-
ably be ideal for therapeutic angiogenesis. It has been
reported that liquid preserved platelet releasates retain
the activity of endogenous growth factors [31]. However,
how to consistently isolate intact and stable (unacti-
vated) platelet concentrates from the bulk plasma envir-
onment remains controversial. Most recent methods of
platelet extract preparation involve the separation of a
fraction abundant in high molecular weight proteins
from low molecular weight soluble components of total
platelet extracts [11,32,33]. Recently, we have optimized
a process for recovery of platelet protein mixtures,
including their separation from the bulk serum proteins,
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of platelet extract preparation we have explored involve
a dialysis step, thus the contribution of low molecular
weight components, such as nucleotides, peptides, and
other small molecules, are likely being lost using this
approach. This could lead to a reduction in the angio-
genic efficacy in these platelet extracts. In this study we
tested the possibility that supplementation of platelet
extracts with exogenous adenine nucleotides may restore
the original potency of platelet extracts and therefore
may modulate angiogenic effects of platelet-derived
growth factors. Using cultured pulmonary artery VVEC
as an angiogenic cell culture model, we investigated the
effects of platelet extracts and adenine nucleotides on
endothelial cell proliferation, migration and tube forma-
tion. Moreover, the angiogenic effects of platelet extracts
and adenine nucleotides were validated in the mouse
Matrigel plug assay. Our study revealed differences
between angiogenic effects of platelet extracts and extra-
cellular adenine nucleotides in vitro and in vivo and
demonstrated that supplementation of platelet extracts
with exogenous adenine nucleotides significantly
potentiates morphogenetic effects of platelet extracts on
Matrigel plug vascularization. These observations sug-
gest that platelet-derived factors and extracellular
nucleotides represent important regulatory signals for
angiogenesis, and that delivery of entire platelet consti-
tuents may be considered as an efficient tool for thera-
peutic angiogenesis and wound healing applications.
Methods
Isolation of platelet extracts
Preserved human platelets were obtained from local
Denver Metro Blood Banks the morning after the mid-
night expiration. The unit containing 200-225 ml was
aliquoted into 6 × 50 ml tubes and then centrifuged at
2,500 × g for 15 min in a tabletop centrifuge (Sorvall
Super T21, rotor ST-H750). After removal of the super-
natant serum, the 6 pellets were resuspended in a
10-15 ml of 6 M urea in PBS and carried through
90 seconds of gentle sonication (Branson sonifier 450,
duty cycle 20%, output control 2). The resulting solution
was then centrifuged at 20,000 × g for 45 min to pellet
out membrane fragments. The final supernatant solution
was dialyzed against 10 mM HCl at 4°C using a 3.5 KDa
cut-off membrane (five one liter exchanges each at least
for 10 hours). After dialysis, protein concentration in
platelet lysates was determined by the Bradford method
and aliquots (15-30 ml) were stored at 4°C [19].
Cultures of vasa vasorum endothelial cells
Pulmonary arteries were obtained from male Holstein
calves that have been exposed to hypobaric hypoxia for
two weeks (PB = 430 mmHg). Adventitia was dissected
from the media, washed and enzymatically digested as
previously described [21]. VVEC were purified from the
co-cultures with adventitial fibroblasts using cloning
rings and trypsinization techniques. Cells were main-
tained in DMEM media supplemented with 10% fetal
bovine serum (FBS) and Endothelial Growth Supple-
ment (Upstate Biotechnology, Charlottesville, VA). Iso-
lated VVEC have been shown to exhibit endothelial
morphology and express endothelial specific markers
including PECAM, eNOS, and VEGFR [34]. All studies
were performed on cells between passages 2 and 7.
Under these conditions, cells sustained consistent func-
tional, morphological, and phenotypical characteristics.
DNA synthesis and cell proliferation assay
Cells were plated in 24 well plates at a density of 1.2 ×
10
4 cells per well in DMEM supplemented with 10%
FBS. On the next day cells were rinsed with phosphate-
buffered saline (PBS), and incubated in DMEM without
serum for 72 hrs. Cells were stimulated with platelet
extracts (6.4, 16 and 64 μg/ml), extracellular ATP
(100 μM), mixtures of MeSATP, ATPgS, MeSADP, and
ADPbS( 1 0 0μM each), or combination of platelet
extracts with adenine nucleotides in the presence of
0.125 μCi of [methyl-
3H] thymidine (NEN Life Science
Products, Boston, MA) for 24 hrs. Incorporated radioac-
tivity was measured using a b-counter as previously
described [21]. To determine the effects of extracellular
nucleotides and platelet extracts on VVEC proliferation,
cells were plated in 96 well plates at a density of 2.4 ×
10
3 cells per well in DMEM supplemented with 1% FBS
and grew for 48 and 60 hrs in the presence of platelet
extracts (6.4, 16 and 64 μg/ml), extracellular ATP
(100 μM), or their combination. Incubation media with
all indicated components were changed daily, and cell
proliferation rate was assessed using CyQuant prolifera-
tion kit (Invitrogen, Carlsbad, CA) according to manufac-
turer’s protocol. Fluorescence intensity was determined
using a plate reader (BMG LABTECH, Germany).
Migration assay
Growth arrested VVEC (1.0 × 10
5 cells/well) were plated
in 200 μl of serum free DMEM on permeable cell culture
inserts (8.0 μM pore size, Costar Inc, Milpitas, CA) pre-
coated with 1% gelatin (Sigma, St. Louis, MO). ATP
(100 μM), platelet extracts (6.4-64 μg/ml) or a combina-
tion of both was added to the lower chamber containing
800 μl of serum free DMEM. After 24-hr incubation, cells
remaining on the upper surface of the filter were wiped
off, and migrated cells were fixed with methanol for
15 min and stained with 0.2% crystal violet in 2% (v/v)
ethanol for a minimum of 15 min. Cells migrated through
the filter were photographed under ×40 magnification of a
phase contrast microscope in six random fields.
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Growth-arrested VVEC (1.25 × 10
5 cells/well in 24-well
plate) were seeded on Growth Factor-Reduced Matri-
gel™ (BD Biosciences, San Jose, CA) in serum-free
DMEM with or without ATP (100 μM), platelet extracts
(16 or 32 μg/ml, as indicated in figure legends) or a
combination of both. Cells were incubated for 10 hrs,
and tube formation was analyzed using a phase contrast
microscope at ×10 magnification. Photographs were
taken using a digital camera connected to a Nikon
microscope. Tube formation was analyzed by S.CORE
Image Analysis (S.CO LifeScience) using three represen-
tative images for each experimental condition.
Evaluation of purinergic receptor subtypes involved in
VVEC angiogenesis
In DNA synthesis, migration and in vitro tube formation
experiments, cells were pre-incubated with P2Y1 recep-
tor antagonist, MRS2179 (2 μM), P2Y13 receptor
antagonist, MRS2211 (25-50 μM, as indicated in figure
legends); non-selective P2Y antagonist, suramin (25-50
μM, as indicated in figure legends), or non-selective
P2Y/P2X antagonist, DIDS (25-50 μM, as indicated in
figure legends) for 45 min prior to stimulation with
extracellular ATP, platelet extracts, or a combination of
ATP and platelet extracts.
In vivo Matrigel plug assay
Aliquots (5-10 μl) of platelet extracts and/or adenine
nucleotides were mixed with 200 μl of Growth Factor-
Reduced Matrigel™ (BD Biosciences) on ice and were
injected subcutaneously into the left and right lower
abdominal side of 50 ICR mice (n = 4-5) using a 26-
gauge needle. Control animals were injected with 200 μl
of Matrigel containing 5-10 μl of vehicle (10 mM HCl).
Each mouse was thoroughly anesthetized using gaseous
isofluorane. After 7 days the animals were sacrificed by
CO2 narcosis followed by cervical dislocation. The plugs
and surrounding tissue were dissected from the abdo-
men and placed in 10% formalin at room temperature
for two days. These were each dissected down the mid-
line of the plug using a razor blade. The halves of each
plug were placed along with the others from the same
treatment into one of two tissue cassettes with the sec-
tioned face down. This produced two “equivalent” slides
of each group of 5 plug halves. The plugs were sec-
tioned at 5-7 microns, stained with hematoxylin and
eosin (H&E) and examined using a compound micro-
scope at ×4-400 magnification. The tubes or capillaries
v i s i b l ea tl e a s t5 0m i c r o n sf r o man a t i v et i s s u ee d g e
were considered to be newly created and not part of
those preexisting in the native tissue. A total of 5-10
fields (×400 magnification) areas were chosen for quan-
tification of tubular structures and functional capillaries.
A capillary was defined as a ring or cylindrical structure
with an internal endothelial cell lining (a lumen) in
which red blood cells could be observed. Tubular forms
(structures) were identical but lacked the presence of
red blood cells. Furthermore, branched tubular forms
were counted as one less than the number of arms (i.e.
a y-shaped structure would be counted as 2, an x shaped
structure as 3, etc) taking two of the arms, most closely
aligned, to be forming one continuous tube. Representa-
tive images of Matrigel plugs were taken using an Olym-
pus BX51 microscope at ×10 to ×40 magnification. To
confirm the microvessel formation in matrigel plugs
immunohistochemical staining with CD-31/PECAM -1
primary antibody (Dianova, Hamburg, Germany; 1:20
dilution) and secondary biotin y l a t e dg o a ta n t i - r a ta n t i -
body (Santa Crus Biotechnology, CA; 1: 200 dilution)
was performed according to the manufacturer’s instruc-
tions. Staining was developed using Chromatogen AEC
Single Solution (Invitrogen, Camarillo, CA). Slides were
counterstained with Hematoxylin (Vector Labs, Burlin-
game, CA).
Statistical analysis
For the analysis of variances between groups of data,
one-way ANOVA was performed followed by Dunnett
or Bonferroni test using GraphPad Prism 3.0 (GraphPad
Software). Data are expressed as the means ± SE; n
equals the number of replicates in one experiment or a
number of observations in independent experiments.
A p value of < 0.05 was considered statistically significant.
Results
Effect of platelet extracts and extracellular nucleotides on
VVEC proliferation
The effects of platelet-derived growth factors on VVEC
mitogenesis were examined using [
3H] thymidine incor-
poration and cell proliferation assays. Data in Figure 1A
demonstrate that platelet extracts at the concentration
of 6.4, 16 and 64 μg/ml significantly increased DNA
synthesis in VVEC. Increased DNA synthesis was also
observed when cells were stimulated with 100 μMA T P
or a mixture of non-hydrolyzable nucleotides, ATPgS,
ADPbS, MeSATP, and MeSADP (100 μM each). The
effect of platelet extract was not significantly enhanced
i nt h ep r e s e n c eo fA T P .H o w e v e r ,i tw a sp o t e n t i a t e di n
cells co-stimulated with platelet extracts (6.4 μg/ml) and
the mixtures of nucleotide analogs.
Cell proliferation assay showed a gradual increase in
cell numbers in response to stimulation with 6.4, 16 and
64 μg/ml of platelet extracts for 48 hrs (Figure 1B). The
stimulatory effects of platelet extract were reduced to
some extent in the presence of 100 μM ATP, although
ATP itself did not have any effect on cell proliferation.
After 60 hrs, a further increase in cell numbers was
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control and platelet ATP-stimulated cells were partially
attenuated in the presence of 16 and 64 μg/ml of plate-
let extracts and 6.4 and 16 μg/ml of platelet extract,
respectively. At both 48 and 60 hrs, proliferative
responses in platelet extract-stimulated cells remained
without significant changes in the presence of 100 μM
ATP. Together, these data demonstrate that in addition
to DNA synthesis response induced by ATP and platelet
extracts, more complex long-term regulatory signals
generated by platelet extracts and extracellular ATP are
necessary for endothelial cell growth.
Effect of platelet extracts and extracellular nucleotides on
VVEC migration
Analysis of VVEC migration in the Boyden chamber
assay demonstrated that platelet extracts at the concen-
tration of 32 μg/ml increased the number of migrated
cells. Noteworthy, clusters of migrated cells were formed
on the underside of the transwell membrane (Figure 2A,
red arrows). ATP had even greater chemotactic effect on
VVEC. Although a number of migrated cells was gradu-
ally decreased when VVEC were co-stimulated with
extracellular ATP and platelet extracts, the migration
response remained statistically significant (compared to
nonstimulated control). In addition, when cells were co-
stimulated with 6.4 μg/ml of platelet extracts and ATP,
the migration response remained statistically significant
compared to the response induced by 6.4 μg/ml of plate-
let extracts alone. Figure 2B shows quantitative analysis
of cell migration from several independent experiments.
Surprisingly, we observed reproducible increases in cell
clustering in response to co-stimulation with ATP and
platelet extracts (6.4, and 32 μg/ml), suggesting that
along with chemotaxis, platelet extracts exerted morpho-
logical rearrangements of endothelial cells.
Effect of platelet extracts and nucleotides on VVEC tube
formation
To further evaluate potential morphogenetic effects of
platelet extracts, we used a Matrigel tube formation
assay in vitro. Incubation of quiescent VVEC on growth
factor-reduced Matrigel for 10 hrs resulted in cell rear-
rangement into aligned and aggregated cell structures
(poorly developed tubes), however no distinguishable
network formation was observed (Figure 3A, panel a).
Incubation of VVEC in the presence of platelet extracts
(16 μg/ml) for 10 hrs resulted in visible cell rearrange-
ments into tube-like networks (Figure 3A, panel b)
evaluated as an increased total length of satisfactory-
developed tubes and a decreased length of poorly-
developed tubes (Figure 3B). The substantial tube
formation effect was also observed in response to extracel-
lular ATP (100 μM) with an increased length of satisfac-
tory- and well-developed tubes and a decreased length of
poorly-developed tubes (Figure 3A, panel c and Figure 3B).
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Figure 1 Effect of extracellular nucleotides on platelet extract-induced mitogenic responses in VVEC. (A): Growth-arrested VVEC (72 hrs in
serum-free DMEM) were stimulated with platelet extracts (6.4, 16 and 64 μg/ml) with or without ATP (100 μM) or a mixture of non-hydrolyzable
nucleotide analogs (MeSATP, ATPgS, MeSADP, ADPbS, 100 μM each) in the presence of 0.125 μCi [
3H]-thymidine for 24 hrs. Incorporated
radioactivity was determined in total cell lysates as described in “Methods”. Data represent the means ± SE from three independent experiments;
* p < 0.05, ** p < 0.01 vs. nonstimulated control; (B): VVEC were grown in DMEM/1% FBS in the presence of platelet extracts (6.4, 16, and 64 μg/
ml), extracellular ATP (100 μM), or combination of both. Incubation media with all indicated components was changed daily. Cell proliferation
rate was assessed using a fluorescent CyQuant proliferation kit (Invitrogen). Data represent the means ± SE from three independent experiments;
* p < 0.05, ** p < 0.01 vs. nonstimulated control (48 hrs); # p < 0.05 vs. nonstimulated control (60 hrs); # # p < 0.05 vs. ATP-stimulated cells (60
hrs). No significant differences were observed between platelet-extract stimulated cells vs. platelet extract- and ATP-stimulated cells at 48 and 60
hrs (p > 0.05).
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ATP (100 μM) resulted in cell rearrangement into a
more distinguishable network pattern with a larger
numbers of interconnected and well-developed tubes,
indicating a potentiating effect of platelet extracts and
ATP on VVEC morphogenesis (Figure 3A, panel d and
Figure 3B).
Involvement of purinergic receptor subtypes in ATP-
stimulated angiogenic responses in VVEC
Our recent studies demonstrated that P2Y1 and P2Y13
purinergic receptors play a predominant role in Ca
2+
and mitogenic responses in VVEC [35]. To further char-
acterize purinergic receptor subtypes in VVEC angio-
genesis, we examined the effects of several purinergic
A
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Figure 2 Effect of extracellular nucleotides and platelet extract on VVEC migration. Growth arrested VVEC (1.0 × 10
5 cells/well) were
plated on top of inserts in serum free DMEM. Cell migration was stimulated by adding platelet extracts (6.4 and 32 μg/ml), ATP (100 μM) or
their combination to the lower transwell compartment. (A): Representative images of migrated cells; arrows indicate network-like structures
(B): Quantitative data represent the means ± SE from four independent experiments on three distinct VVEC populations; * p < 0.05, ** p < 0.01
vs. nonstimulated control; # # p < 0.01 platelet extract-stimulated cells vs. platelet extract- and ATP-stimulated cells.
Roedersheimer et al. Vascular Cell 2011, 3:4
http://www.vascularcell.com/content/3/1/4
Page 6 of 15receptor antagonists on VVEC DNA synthesis, migra-
tion and tube formation. Pre-treatment of VVEC with
suramin (non-selective P2Y receptor antagonist),
MRS2179 (P2Y1 selective receptor antagonist),
MRS2211 (P2Y13 selective receptor antagonist), and
DIDS (P2Y/P2X non-selective receptor antagonist) sig-
nificantly inhibited DNA synthesis in response to ATP
(Figure 4A). Pre-treatment with suramin, MRS2179, but
not MRS2211 and DIDS significantly reduced DNA
synthesis in response to a combination of ATP and pla-
telet extracts. Surprisingly, pre-treatment with suramin,
MRS2211, and DIDS also reduced DNA synthesis
response to platelet-extract, suggesting that endogenous
purinergic receptor ligands from these mixtures contri-
bute to VVEC mitogenesis. In addition, according to
some reports, the inhibitory effect of suramin can be
due to the interference of growth factor-receptor bind-
ing [36].
We also found that suramin, MRS2179, MRS2211, and
DIDS all significantly reduced VVEC migration in
response to ATP, but only modestly, in response to sti-
mulation with ATP in a combination with platelet
extracts (Figure 4B). Potent inhibitory effects of suramin
and DIDS on VVEC migration may indicate that in
addition to P2Y13 and P2Y1, additional subtypes of P2Y
and P2X receptors contribute to nucleotide-induced
VVEC migration.
The effects of purinergic receptor antagonists were
further evaluated in the in vitro tube formation assay.
Representative images for each condition are shown in
Figure 4C. Pre-treatment of VVEC with suramin had a
potent inhibitory effect on VVEC tube formation under
each condition tested. Pre-treatment of VVEC with
MRS2179 decreased tube formation in response to ATP,
platelet extracts, and combination of ATP with platelet
extracts. Pre-treatment with MRS2211 decreased tube
formation in response to ATP and the combination of
ATP with platelet extracts, whereas tube formation in
response to platelet extracts was less affected. Pre-
treatment with DIDS had a small effect on ATP-induced
tube formation, modest effects on platelet extract-
induced tube formation, and potent effect on tube for-
mation stimulated by combination of ATP and platelet
extracts. Together, these data show a differential
a b
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Figure 3 Platelet extracts and extracellular ATP elicit VVEC rearrangements into tube-like network on Matrigel. (A): Growth-arrested
VVEC (1.25 × 10
5 cells/well) were plated on growth factor-reduced Matrigel in serum free DMEM. Formation of tube-like networks was
stimulated by the addition of platelet extracts (16 μg/ml), ATP (100 μM), or combination of both. After incubation, images were captured in
three fields using Nikon microscope connected with digital camera. The data show one representative image for each experimental conditions;
arrows indicate cells visible within the Matrigel; (B): Quantitative evaluation of tube formation using S.CORE Image Analysis. Data represent the
means ± SEM of three independent experiments; # p < 0.05, # # p < 0.05, vs. nonstimulated control (total length of poorly-developed tubes),
* p < 0.05, *** p < 0.001 vs. nonstimulated control (total length of satisfactory-developed tubes), § p < 0.05 vs. nonstimulated control (total
length of well-developed tubes).
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Figure 4 Contribution of purinergic receptor subtypes in angiogenic responses to extracellular ATP in VVEC. (A): Growth-arrested cells
were pre-incubated with purinergic receptor antagonists suramin (25 μM), MRS2179 (2 μM), MRS2211 (25 μM) or DIDS (25 μM) for 45 min or
remained untreated and then stimulated with ATP (100 μM) in the presence of 0.125 μCi [
3H]-thymidine for 24 hrs. Incorporated radioactivity
was measured in total cell lysates using a b counter. Data represent means ± SE from four independent experiments conducted on two distinct
VVEC populations; ** p < 0.01 vs. control; § p < 0.05, §§ p < 0.01 - platelet extract-stimulated cells vs. platelet extract-stimulated cells treated
with antagonists; # p < 0.05, ## p < 0.01 ATP-stimulated cells vs. ATP-stimulated cells treated with antagonists; non-stimulated control; @ p <
0.05, @@ p < 0.01 ATP- and platelet extract-stimulated cells vs. ATP- and platelet extract-stimulated cells treated with antagonists; (B) Growth
arrested cells were placed on top of inserts in serum free DMEM and pre-treated with suramin (50 μM), MRS2179 (2 μM), MRS2211 (50 μM) or
DIDS (50 μM) for 45 min or remained untreated. Cell migration was stimulated by adding platelet extracts (32 μg/ml), ATP (100 μM) or their
combination to the lower transwell compartment. Quantitative data represent the means ± SE from three independent experiments; ** p < 0.01,
***p < 0.001 vs. control; § p < 0.05 - platelet extract-stimulated cells vs. platelet extract-stimulated cells treated with antagonists; # p < 0.05,
## p < 0.01 ATP-stimulated cells vs. ATP-stimulated cells treated with antagonists; (C) Growth-arrested VVEC were plated on growth factor-
reduced Matrigel in serum free DMEM and pre-treated with purinergic receptor antagonists as described above in the panel A. Tube formation
was stimulated by the addition of platelet extracts (32 μg/ml), ATP (100 μM), or a combination of both. Data show images from one
representative experiment. Similar results were obtained in at least three experiments conducted on distinct VVEC populations.
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The effects are mediated presumably by P2Y1, P2Y13
and possibly, P2Y2 receptors. The role of P2X receptors
requires more specific evaluation using selective agonists
and antagonists.
Effect of platelet extracts and nucleotides on Matrigel
plug neovascularization in vivo
Considering the observed morphogenetic effects of pla-
telet extracts and extracellular ATP on VVEC, we next
examined the effect of these angiogenic modulators
using the in vivo Matrigel plug assay. Subcutaneous
injection of 200 μl of growth factor-reduced Matrigel in
50 ICR mice did not induce neovessel formation in the
Matrigel plugs above that typically seen with Matrigel
alone (Figure 5, panel a; Figure 6A). Injection of Matri-
gel supplemented with 58 μg/ml platelet extracts gave
an increased number of tubes per plug, changing from
3.2 observed in the control (n = 4) to 7.5 (n = 3); (Fig-
ure 5, panel b; Figure 6A). The effect of 29 μg/ml plate-
let extract on tube formation in vivo was not statistically
significant (Figure 6B).
Furthermore, the effects of adenine nucleotides on
Matrigel plugs vascularization were evaluated. Data in
Figure 5 show that injection of Matrigel supplemented
with either ATP (1 mM) or mixtures of non-hydrolyzable
Figure 5 The effects of platelet extracts and adenine nucleotides on Matrigel plug vascularization. Matrigel (200 μl per plug) was mixed
with platelet extracts (29 μg/ml and 58 μg/ml), ATP (1 mM), mixture of MeSATP, ATPgS, MeSADP, and ADPbS (0.1 mM, 0.5 mM or 1 mM of
each), combination of nucleotides and platelet extracts (concentrations as indicated), or vechicle (10 mM HCl in PBS) and injected
subcutaneously into ICR mice (n = 4-5 for each group). After 7 days, mice were sacrificed, Matrigel plugs were excised, and 5-7 μm-thick sections
were prepared from formalin fixed plugs/paraffin-embedded plugs. H&E staining was performed for identification of plug cellularity and tube
formation. Representative images show (a): control plugs, ×40; (b): plugs containing 58 μg/ml platelet extract (×40; insert shows magnified view
of an capillary containing red blood cells); (c-d): plugs containing 0.5 mM purine nucleotides (panel c = ×40, panel d = x10 magnification; arrows
on the panel c indicate areas of increased plug cellularity); platelet extracts (58 μg/ml), mixture of MeSATP, ATPgS, MeSADP, and ADPbS (0.1 mM,
0.5 mM or 1 mM of each), (e-f): plugs containing platelet extracts (58 μg/ml) and mixture of nucleotides (0.5 mM of each); panel e: plug with
increased amount of functional capillaries (enlarged in the insert); panel f: blood cell infiltrates around new formed capillaries (enlarged in the
insert); (g-j): Identification of PECAM-positive cells in control plugs (g) and plugs containing 58 μg/ml platelet extract (h), mixture of nucleotides
(0.5 mM of each), and combination of 58 μg/ml platelet extract and mixture of nucleotides (0.5 mM of each, j). PECAM-positive cells are shown
enlarged in the inserts.
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Figure 6 Quantitative analysis of tube formation in nucleotide-containing Matrigel plugs. Data in panels A-C represent means ± SE for
the amount of tubes detected in right- and left-side placed plugs for each animal in the group. Five to ten random fields were analyzed per
each section. (A): Tube formation in control and platelet extract containing Matrigel plugs (concentrations as indicated). Total number of tubes
per animal group were use for statistical analysis of variances; p > 0.05 and p < 0.05 vs. control group; (B): Tube formation in Matrigel plugs
containing ATP or mixtures of MeSATP, ATPgS, MeSADP, and ADPbS (concentrations as indicated). Total number of tubes per animal group were
use for statistical analysis of variances; p > 0.05 vs. control group, shown in panel A); (C): Tube formation in Matrigel plugs containing platelet
extracts and mixtures of MeSATP, ATPgS, MeSADP, and ADPbS (concentrations as indicated); *p < 0.05 vs. nucleotides alone, **p < 0.01 vs.
nucleotides alone); (D): Summary of the analysis of tube formation for all experimental conditions. Data are mean ± SE for the total amount of
tubes for each group; *p < 0.05 vs. control; # p < 0.05 vs. nucleotides alone; # # p < 0.01 vs. nucleotides alone; (E): Quantitative analysis of
functional capillaries in Matrigel plugs. The capillaries of at least 50 microns from a native tissue edge were considered newly created within the
plug and were not part of those preexistent in the native tissue. Five to ten random fields were analyzed per each section. Data are means ± SE
(n = 5) for each condition; *p < 0.05 vs. control; **p < 0.01 vs. control # p < 0.05 vs. nucleotides alone; # # p < 0.01 vs. nucleotides alone.
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and 1 mM of each) did not result in increased Matrigel
plug vascularization (Figure 5panels c, d). The number of
tubes per plug was lower than in the control group (Fig-
ure 6B). Notably, a considerable variability in Matrigel
vascularization was observed between individual animals
within the group. Moreover, visible infiltration of inflam-
matory cells was observed in ATP supplemented Matri-
gel plug retrieved from one animal (Figure 5, panel d).
Since ATP potentiated the effect of platelet extract on
VVEC tube formation in vitro, it was expected that a
similar effect would be observed in plug vascularization
in vivo.D a t ai nF i g u r e5 ,panel e show that subcuta-
neous injection of Matrigel supplemented with mixtures
of non-hydrolyzable nucleotides, ATPgS, ADPb,
MeSATP, and MeSADP (each 0.1, 0.5 or 1 mM) and
platelet extracts (58 μg/ml) resulted in the enhanced for-
mation of tubular structures and functional capillaries in
Matrigel plugs. In addition, in some plugs, blood infil-
trates can be observed, suggesting that some neovessels/
immature blood conduits, prone to rupture, might have
formed there (Figure 5, panel f). The tube numbers in
nucleotide -containing plugs were almost the same for
each nucleotide concentration, and these numbers were
lower than those in the plugs supplemented with plate-
let extracts only (Figure 6C). Data in figure 6D summar-
ize the results of Matrigel plug vascularization for all
experimental groups. A statistically significant increase
in number of tubes was observed in Matrigel plugs con-
taining 58 μg/ml platelet extracts and 58 μg/ml in com-
bination with nucleotide mixtures. Remarkably, the
combination of platelet extracts and nucleotides also
gradually increased the number of functional capillaries;
the most dramatic effect was observed in Matrigel plugs,
supplemented with 0.5 and 1 mM of nucleotides (Figure
6E). Histological evaluation of Matrigel plugs suggested
that both immature tubular structures and functional
capillaries could be expected in Matrigel plugs. To
confirm the microvessel formation, plugs were immu-
nostained for CD31/PECAM-1. The number of
PECAM-1-positive endothelial cells was higher in Matri-
gel plug supplemented with platelet extracts, ATP, and
mixtures of nucleotide analogs compared to control
plugs (Figure 5C, panels g-j).
Altogether, the results from our in vitro and in vivo
studies suggest that platelet extract and adenine nucleo-
tides promote distinct but likely complementary signal-
ing events, leading to functional neovessel formation.
Discussion
Development of improved strategies for therapeutic
angiogenesis remains an imperative task for treatment
of a variety of pathological conditions. Of all the
circulating blood cells, platelets are the most abundant
sources of endogenous angiogenic regulators. In this
study we challenged the hypothesis that combination of
platelet-derived factors with extracellular nucleotides,
also known as regulators of the vascular growth, would
have even more potent angiogenic effects in vitro and in
vivo. Our data demonstrated that platelet extracts and
extracellular adenine nucleotides exerted similar, but
not identical effects on endothelial proliferation, migra-
tion and tube formation. The main conclusion from this
study is that extracellular adenine nucleotides modulate
angiogenic effects of platelet extracts in vitro and,
importantly, lead to a greater amount of functional
capillary formation in Matrigel plugs in vivo.
As mentioned above, platelets contain multiple consti-
tuents including angiogenic mediators, extracellular
matrix components, nucleotides, sugars, growth factors,
antimicrobial peptides, and cytokines that can support
wound healing and angiogenesis [6-8,12,14,30,33]. Angio-
genic effects of platelets have been previously demon-
strated in several model systems. Recent reports have
shown some examples that platelet rich plasma (PRP)
and platelets can substitute for animal serum as a nutri-
ent source for human cells in culture and therefore, may
have the capacity to provide nourishment or survival fac-
tors to cells at risk from the compromised vascular sup-
ply at a wound site [[37,38] and Mark Roedersheimer,
unpublished observation]. It was demonstrated, that a
potent chemotactic and angiogenic activity is generated
by factors released from activated platelets [7,9,30]. The
presence of platelets not only stimulates vessel growth
but also plays a critical role in preventing hemorrhage
from the angiogenic vessels [11] supporting a theory of
functional link between hemostasis and angiogenesis.
However, despite a strong evidence of angiogenic
effects of platelets, there is also some degree of skepti-
cism about the utility of platelet-derived components for
a modulation of angiogenesis due to a high degree of
variability in clinical outcomes, which are probably asso-
ciated with: (i) lack of sufficient release of key growth fac-
tors following an incomplete platelet “activation” with a
single factor, such as thrombin, during PRP preparation;
(ii) failure to separate the platelet-derived growth factors
from the bulk of the highly concentrated serum compo-
nents, which may limit bioavailability; (iii) failure to
determine at least the protein concentration of the active
platelet extract (separated from the plasma) and using
this to establish a proper dosing; and iv) variability in the
composition, and therefore activity, of platelet extracts
from different individuals that may need to be accounted
for in the dosing. Reducing variability in the clinical
response to PRP remain as important goal in bringing
platelet extract preparation methods to full utility.
Roedersheimer et al. Vascular Cell 2011, 3:4
http://www.vascularcell.com/content/3/1/4
Page 11 of 15In the present study we demonstrated that total cell
extracts isolated from preserved platelets have an angio-
genic potential. Our approach of using total platelet
extracts assumed that a crude extract isolated by a lysis
of platelet pellet, even though lacking the ability of
intact platelets to sense and respond to signals in a tis-
sue environment, can still be used to produce a
balanced regenerative response in a tissue. According to
our established procedure, soluble platelet extracts were
prepared by platelet sonication and subsequent stabiliza-
tion of soluble components through the dialysis of cellu-
lar extract against 10 mM HCl in a 3.5 KDa cut-off
membrane. Based on some reports, mildly acidic envir-
onment (also typical for wound sites) may possibly opti-
mize the stability and activity of platelet-derived factors
such as PDGF and TGFb [39,40]. However, the dialysis
step removes small molecular weight soluble compo-
nents, including nucleotides and amino acids from the
fraction of growth factors and cytokines. Therefore, it
can be assumed that when platelet extract preparation
includes a dialysis step, supplementation (or “recon-
struction”) of dialyzed platelet extracts with exogenous
adenine nucleotides could modulate or potentially
enhance the angiogenic effects of platelet-derived
extracts.
A variety of pathological conditions in the vasculature
is accompanied with elevated levels of extracellular ATP
and ADP, platelet immobilization, activation, and their
adhesion to endothelial cells, with ultimate endothelial
cell activation. These events may possibly lead to angio-
genesis and initiation of vascular regeneration processes
[23,41-44]. Activated platelets release factors capable of
promoting hematopoietic stem cell migration into a vas-
cular injury site and their differentiation into endothelial
cells, which may favor survival via angiogenic signaling
pathways [32,45]. We expect that extracellular nucleo-
tides released from platelets and endothelial cells could
act in concert with multiple growth factors and cyto-
kines. Previously, we demonstrated that extracellular
ATP exerts dramatic effects on VVEC mitogenesis,
migration and tube formation [21,23]. However, angio-
genic effects of extracellular nucleotides in the in vivo
models of angiogenesis, as well as combined effects of
extracellular nucleotides and platelet-derived growth fac-
tors on angiogenesis have not yet been investigated. Our
present study provides new evidence that platelet-
derived extracts and adenine nucleotides exerted diverse,
but complementary angiogenic effects in isolated VVEC.
Platelet extract induced DNA synthesis and affected
proliferative responses in VVEC. The proliferative
r e s p o n s ew a sa ti t sh i g h e s ta t4 8h r s ,f o l l o w e db ya
decrease at 60 hrs. This biphasic effect may suggest a
possibility that the initial increase in VVEC proliferation
m a yb ef o l l o w e db ym o r el o n g - t e r mr e g u l a t o r ys i g n a l s
leading to endothelial differentiation, stabilization and/
or morphological changes. Strikingly, extracellular ATP,
despite strong effects on DNA synthesis, did not induce
VVEC proliferation and to some extent diminished pro-
liferative responses induced by platelet extracts mea-
sured at 48 hrs, again, suggesting prolonged and more
complex integrative signaling events underlying the
action of extracellular nucleotides and platelet-derived
angiogenic factors.
Our study also revealed differences in extracellular
ATP- and platelet extract-induced migratory responses.
Extracellular ATP had a more potent effect (~75- fold)
on VVEC migration in contrast to the effect induced by
platelet extracts (~7-20-fold). However, more dramatic
effects (up to 65-fold) can be observed in response to pla-
telet extracts derived some units of preserved human pla-
telets (Figure 4B and unpublished observations).
Interestingly, in response to extracellular ATP all
migrated VVEC adhered to and spread uniformly on the
underside of the transwell chamber membrane, whereas
in response to platelet extracts, aggregates of migrated
cells were observed on the underside of the membrane.
We also found that platelet extracts, in a concentration-
dependent manner, diminish ATP-induced VVEC migra-
tion, which was accompanied by a more dramatic cell
clustering on the underside of the chamber membrane.
Similar to our findings, a recent study by O’Connor
demonstrated “adherent migration” of THP-1 in response
to platelet soluble fractions [33], suggesting that even in
the migration assay setting, platelet extracts induce struc-
tural and adhesive changes in endothelial cells. This mor-
phogenetic effect of platelet extract was further
demonstrated in the Matrigel tube formation assay. We
found that platelet extract and extracellular ATP were
almost equipotent in the induction of satisfactory-
developed tubes on growth factor-reduced Matrigel. In
addition, the total number of well-developed tubes was
significantly increased when VVEC were co-stimulated
with platelet extracts and extracellular ATP. Together,
the in vitro studies demonstrated that both extracellular
ATP and platelet extracts exert angiogenic effects in
VVEC, but only morphogenetic effect was potentiated in
response to the combined action of extracellular ATP
and platelet extracts. Further investigation is necessary to
define molecular mechanisms contributing to intracellu-
lar signaling cross-talk initiated by purinergic receptors
and receptor tyrosine kinases in VVEC.
Recenty, we demonstrated a predominant involvement
of P2Y1 and P2Y13 receptors in Ca
2+ and mitogenic
response in VVEC [35]. In this study we further investi-
gated a contribution of purinergic receptor subtypes in
VVEC angiogenesis. Using an antagonist approach, we
demonstrated an involvement of P2Y1 and P2Y13 recep-
tors in ATP-induced DNA synthesis and tube formation,
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migration. An inhibitory effects of suramin (non-
selective P2Y antagonist) on ATP-induced DNA synth-
esis and tube formation may also suggest a contribution
of P2Y2 receptors in these angiogenic responses. In
addition, potent inhibitory effects of DIDS on DNA
synthesis, migration, and, to a lower extent, tube forma-
tion may suggest an involvement of P2X receptors in
mediating nucleotide signaling in VVEC. We also found,
that some angiogenic effects of platelet extract, although
to a different degree, can be attenuated by purinergic
receptor antagonists (suramin and MRS2179). Whether
this can be explained by the presence of residual endo-
genous nucleotides or other purinergic receptor ligands
(such as cysteinyl leukotrienes) in platelet extracts
remains to be determined and represents an interesting
possibility for future investigations.
Consistent with the results from the in vitro studies,
platelet-derived extracts displayed a dose-dependent
angiogenic response in the Matrigel plug assay in 50
ICR mice. The effect was evaluated in terms of the
number of tube-like structures, as well as functional
capillaries containing red blood cells sufficiently far
f r o man a t i v et i s s u eb o u n d a r yt oe x c l u d et h e i rp r e e x i s -
tence. We have previously shown that even very low
concentrations of platelet-derived extracts (<50 μg/ml)
speeded up the healing process of incision wounds
placed on the backs of mice (unpublished observation).
However, some variations in minimal effective concen-
tration of platelet extracts were observed among human
plasma sources. For instance, platelet extracts used in
this study exhibit the highest activity at concentrations
between 16 and 64 μg/ml. The functionality of capil-
laries in Matrigel plugs was evaluated based on micro-
scopic detection of erythrocytes within the capillary
lumen, suggesting a link to the systemic circulation. In
agreement with the in vitro data, we observed increased
formation of tube-like structures in Matrigel plugs sup-
plemented with platelet extract. Despite a number of
studies showing angiogenic effects of extracellular
nucleotides in various cell systems, the angiogenic
effects of extracellular nucleotides in the in vivo Matri-
gel plug model have not been previously investigated.
To our surprise, tube formation in the Matrigel plugs
supplemented with extracellular ATP was even lower
than the tube formation in the control plugs.
It would have been expected that extracellular ATP
might be hydrolyzed to adenosine by endothelial and
blood cell ecto-nucleotidases, resulting in decreased
plug vascularization. Therefore, we evaluated the effect
non-hydrolyzable nucleotide analogs, ATPgS, ADPbS,
MeSATP, MeSADP. No additional tube formation was
observed in response to these nucleotides, suggesting
that decreased plug vascularization in response to ATP
could not be explained by its hydrolysis to adenosine.
Remarkably, we found more cellularity in some Matrigel
plugs, containing mixtures of high concentrations of
extracellular nucleotides (1 mM). Considering that
monocytes/macrophages and endothelial progenitor cells
may contribute to neovascularization, and can be
attracted by platelet-derived microparticle components
[32,46-49], we speculate that inflammatory and/or pro-
genitor cells may also contribute to angiogenic
responses in Matrigel plugs. This possibility will be
further investigated in our laboratory. Histological eva-
luation of Matrigel plugs revealed that both immature
tubular structures and functional capillaries were
formed. Although tube formation in the Matrigel plugs,
supplemented with extracellular ATP was even lower
than the tube formation in the control plugs, higher
numbers of functional capillaries and PECAM -positive
cells were observed in ATP and nucleotide-containing
Matrigel plugs compared to control. In some plugs,
blood infiltrates were found in addition to well-formed
capillary structures, indicating that newly-formed vessels
could be, at least in part, immature and leaky. In the
meantime, the amount of functional capillaries and
PECAM-positive cells was even higher in Matrigel plugs
containing platelet extracts and nucleotides (compared
to Matrigel plugs containing either nucleotide or platelet
extract). These observations are consistent with the idea
that extracellular nucleotides and platelet -derived
growth factors provide complementary regulatory signals
necessary to promote neovessel growth and maturation.
Conclusions
In conclusion, our study provides new evidence for the
angiogenic effects of platelet-derived extracts in combi-
nation with extracellular adenine nucleotides. These
results shed new light on the role of platelets and extra-
cellular nucleotides in the regulation of vascular hemos-
tasis and angiogenesis. Our findings could be clinically
applicable for the optimization of wound healing, tissue
engineering or vessel stabilization, important in many
pathological conditions, such as those observed in
tumor and diabetes complications.
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